EXHIBIT 99.1

Contacts:

Jeremy Price                                           Fredda Malkoff
Manager, Investor Relations                            Account Director
BioMarin Pharmaceutical Inc.                           Feinstein Kean Healthcare
(415) 884-6777                                         (617) 577-8110
jprice@biomarinpharm.com                               fmalkoff@fkhealth.com

For Immediate Release:

           BioMarin Announces Positive Findings from Phase 1 Trial and
                   Extension Study of AryplaseTM for MPS VI

Novato,  California,  June 25th, 2002 - BioMarin Pharmaceutical Inc. (Nasdaq and
Swiss  SWX  New  Market:  BMRN)  today  announced  findings  from  the  24-week,
open-label  extension  portion  of the Phase 1  clinical  trial of  Aryplase(TM)
(recombinant  human  arylsulfatase  B), an  investigational  enzyme  replacement
therapy for  mucopolysaccharidosis  VI (MPS VI). Data from the  extension  study
indicate that Aryplase continues to be well-tolerated at both dose levels by the
five patients who have received treatment for a total of 48 weeks.

In  addition,  the 1.0 mg/kg  dose  continued  to  produce  a greater  sustained
reduction than the 0.2 mg/kg dose in the excretion of urinary glycosaminoglycans
(GAGs) over 48 weeks.  The reduction in urinary GAGs  indicates that Aryplase is
breaking down the complex  carbohydrate  materials that otherwise  accumulate in
patients with MPS VI and lead to the debilitating and life-threatening  symptoms
of the disease.

On Saturday, June 22, Paul Harmatz, M.D., Associate Director, Pediatric Clinical
Research Center, Children's Hospital and Research Center at Oakland, California,
presented 48 weeks of data from the Phase 1 Aryplase  trial,  which  includes 24
weeks  of data  from  the  ongoing  extension  study,  at the 7th  International
Symposium on Mucopolysaccharide and Related Diseases in Paris, France.

Dr. Harmatz,  the Phase 1 trial's  principal  investigator,  noted,  "During the
first 24 weeks of  treatment,  most  observable  improvements  were  seen in the
patients with more advanced disease.  I was pleased to begin to see improvements
in the less advanced patients after nearly a full year of treatment."

In  September  2001,  BioMarin  reported  results  from a  24-week,  randomized,
double-blind  six-patient  Phase 1  clinical  trial  of  Aryplase.  The  primary
objective of this trial and the  corresponding  extension  study was to evaluate
the safety of Aryplase at two dose levels:  0.2 mg/kg and 1.0 mg/kg. One patient
from the 0.2 mg/kg  treatment  arm withdrew  from the trial during the extension
period.  This  withdrawal was not due to any  Aryplase-related  serious  adverse
events.



During both the  double-blind  and extension study periods,  the enzyme was well
tolerated by all patients. Key findings included:

   o No treatment-related serious adverse events;
   o No significant allergic reactions to the enzyme infusions;
   o Reduced urinary GAG excretion was maintained in both treatment arms;
   o The 1.0 mg/kg dose, which produced a greater initial reduction in the
     excretion of urinary GAGs, continued to demonstrate a greater sustained
     reduction over 48 weeks.

In March 2002,  BioMarin  initiated a Phase 2 clinical  trial of  Aryplase.  The
primary objective of this open-label,  multi-national  Phase 2 clinical trial is
to evaluate the  efficacy,  safety and  pharmacokinetics  of weekly  intravenous
infusions of 1.0 mg/kg of Aryplase in 10 MPS VI patients.  This dose  represents
the higher level of two doses administered in the Phase 1 trial.

In addition, following the 48-week evaluation, all five patients who continue to
receive  treatment as part of the Phase 1 extension  study are now receiving the
1.0 mg/kg dose of Aryplase.

About MPS VI

MPS VI is a  life-threatening  lysosomal storage disorder caused by a deficiency
of the enzyme N-acetylgalactosamine 4-sulfatase (also known as arylsulfatase B).
This  deficiency  leads  to the  accumulation  of  GAGs  in the  lysosomes,  the
digestive organs of the cell. The accumulation of GAGs in the lysosomes leads to
progressive cellular, tissue and organ system dysfunction. Debilitating symptoms
often  include  impaired  cardiac  and  pulmonary  function,   delayed  physical
development,  skeletal and joint deformities, impaired vision and hearing, sleep
disorders,  and reduced  endurance.  Depending  on the  severity of the disease,
patients die from  disease-related  complications  between  childhood  and early
adulthood.

BioMarin  specializes in the  development and  commercialization  of therapeutic
enzyme products to treat serious, life-threatening diseases and conditions.

This  press  release  contains  forward-looking  statements  about the  business
prospects of BioMarin  Pharmaceutical  Inc. and its  potential  future  product,
Aryplase  for the  treatment  of MPS VI. These  forward-looking  statements  are
predictions  and involve risks and  uncertainties  such that actual  results may
differ materially from these statements. Results may differ materially depending
on the  progress  of  BioMarin's  product  programs,  the actual  results of the
current and planned clinical trials and the possible  revision of the results of
the trials that were  presented at the above  described  conference,  actions of
regulatory  authorities,  and those factors detailed in BioMarin's  filings with
the  Securities  and  Exchange  Commission  such  as 10Q,  10K  and 8K  reports.
Stockholders   are  urged  not  to  place  undue  reliance  on   forward-looking
statements,  which  speak  only as of the  date  hereof.  BioMarin  is  under no
obligation,  and  expressly  disclaims  any  obligation,  to update or alter any
forward-looking statement, whether as a result of new information, future events
or otherwise.